Description: ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Home Page: www.reneuron.com
Pencoed Business Park
Pencoed,
CF35 5HY
United Kingdom
Phone:
44 20 3819 8400
Officers
| Name | Title |
|---|---|
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman |
| Mr. John Michael Hawkins A.C.A. | Company Secretary, CFO & Director |
| Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder |
| Ms. Suzanne Hancock | Chief Operations Officer |
| Dr. Randolph Corteling Ph.D. | Chief Scientific Officer |
| Mr. Simon Dew | Chief Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.4046 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.686 |
| Price-to-Sales TTM: | 9.0699 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 26 |